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Background: In Europe, epoetin subsequent entry biologics (SEBs) have been in use since 2007. Canadian patents
of erythropoietin stimulating agents are expiring in 2014, therefore it is predicted that epoetin SEBs will penetrate
the Canadian market in the near future.
Objective: To estimate the economic impact and costs offsets associated with the uptake and use of one or more
epoetin SEBs in Canada for the treatment of anemia in chronic kidney disease.
Design: A Canada-wide epidemiological-based budget impact analysis was conducted to estimate cost outcomes
under two scenarios: with and without the availability of epoetin SEB.
Setting: The analysis was conducted from the perspective of the Canadian healthcare payer, over a 5-year time
horizon from 2015 to 2019.
Patients: Patients included in the model were those with chronic kidney disease stages 3 to 5, who have renal
anemia and require treatment with erythropoietin stimulating agents.
Methods: Only direct medical costs pertaining to drug acquisition of currently available erythropoietin stimulating
agents in Canada were incorporated in the model. Cost of epoetin SEBs, market shares, uptake rates, and other
model inputs were estimated from published sources or databases. No discounting of future costs was applied.
Results: Based on our analysis, under market phenomena similar to those seen in the Europe and without
considering potential switching from originator epoetin to epoetin SEB, we could expect that Canadian adoption of
epoetin SEBs could result in $35 million (2013 CAD, year 1) to $50 million (year 5) cost savings annually, with
cumulative savings of $221 million after 5 years. In one-way sensitivity analyses, model variables with substantial
impact on cost savings were the prevalence of chronic kidney disease and epoetin SEB uptake rates.
Limitations: We did not take into account costs associated with overhead, administration, or adverse events.
Conclusion: The advent of SEBs represents an opportunity to relieve financial pressure in our healthcare system.
Under the assumption that the efficacy and safety of epoetin SEBs are non-inferior to originator products, we have
shown that the adoption of epoetin SEBs can lead to cost savings for the Canadian payer.
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Contexte: L’époétine biosimilaire est utilisée en sol européen depuis 2007. Puisque les brevets d’utilisation des
agents stimulant l’érythropoïèse (ASE) viennent à échéance en 2014, il est à prévoir que l’époétine biosimilaire, qui
est un produit biologique ultérieur, fera son entrée sur le marché canadien dans un avenir rapproché.
Objectifs: Estimer l’impact économique et les coûts de compensation qui découlent de l’utilisation d’une ou de plusieurs
formes d’époétines biosimilaires, dans le traitement de l’anémie associée à la maladie rénale chronique, au Canada.
Type d’étude: Une analyse d’impact budgétaire pancanadienne basée sur des données épidémiologiques a été réalisée
afin d’estimer les coûts reliés à deux scénarios éventuels: le premier avec époétine biosimilaire sur le marché, et le
deuxième sans cette disponibilité.
Contexte: L’analyse a été menée à partir de la perspective du contribuable au système de soins de santé canadien, sur
un horizon de cinq ans, soit de 2015 à 2019.
Participants: Le modèle ne tient compte que des patients atteints d’une maladie rénale chronique de stades 3 à 5,
souffrant d’anémie reliée à la maladie rénale, et nécessitant un traitement avec des agents stimulant l’érythropoïèse.
Méthodes: Les seuls coûts pris en compte par le modèle sont les coûts médicaux directs découlant de l’achat des agents
stimulant l’érythropoïèse disponibles au Canada. Les coûts reliés à l’époétine biosimilaire, les parts de marché, les coûts de
compensation, et les autres entrées du modèle ont été estimés à partir de sources publiées ou de bases de données.
Aucune actualisation des coûts futurs n’a été estimée.
Résultats: Selon notre analyse, qui ne tient pas compte de la possibilité d’utiliser l’époétine biologique de référence avant
de passer à l’époétine biosimilaire, et sous des conditions de marché similaires à celles observées en Europe, l’adoption à
l’échelle canadienne de l’époétine biosimilaire pourrait résulter en une économie de 35 millions $ (2013 $ CAN, année 1)
à 50 millions $ (année 5) par année, pour une économie cumulative potentielle de 221 millions $ après cinq ans. L’analyse
de sensibilités unidirectionnelles montre que la prévalence de la maladie rénale chronique et les coûts de compensation
reliés à l’époétine biosimilaire sont les variables du modèle ayant le plus d’impact économique.
Limites de l’étude: Nous n’avons pas tenu compte des frais généraux, d’administration, ou découlant d’imprévus.
Conclusion: Les produits biologiques ultérieurs peuvent aider à alléger les difficultés financières de notre système de
santé actuel. En supposant que l’époétine biosimilaire présente une efficacité et une innocuité qui ne sont pas inférieures
à celles des époétines biologiques de référence, nous montrons que l’utilisation de l’époétine biosimilaire peut mener à
des économies pour le contribuable canadien.What was known before: Canadian patents for epoetin alfa
and darbepoetin alfa are expiring, as such there is an oppor-
tunity to reduce expenditure on erythropoiesis-stimulating
agents (ESAs) by adopting subsequent entry biologics
(SEBs). In Europe, epoetin SEBs have been introduced at
lower prices than innovator epoetins and have been in use
since 2007.
What this paper adds: To date, published studies have
only examined the budget impact of epoetin SEBs for the
management of chemotherapy-induced anemia in European
countries. This analysis takes the market experience of epoe-
tin SEBs in Europe and models the economic impact of the
introduction of these SEBs into the Canadian landscape.
Our results serve to inform Canadian stakeholders including
our policy makers, budget holders, researchers, and
clinicians.
Background
Over the last two and a half decades, the ESAs epoetin
alfa (Eprex®) and darbepoetin alfa (Aranesp®) havebecome the standard of care for treating patients with
anemia of chronic kidney disease (CKD) in Canada.
With Canadian patents expiring in May 2014 and Au-
gust 2014, respectively [1], there is an opportunity to re-
duce expenditure on ESAs by using “copies” of these
innovator biologics called SEBs. In Europe, epoetin SEBs
have been in use since 2007 [2]. Therefore, we predict
companies will submit at least two epoetin SEBs to
Health Canada for evaluation before the end of 2015.
With no Canadian economic analyses published on
this subject to date, we conducted a budget impact
analysis (BIA) to estimate the financial impact of
these agents in treating anemia of CKD in the
Canadian setting.
A BIA is an essential part of economic evaluations for
healthcare interventions. Reimbursement authorities in-
creasingly utilize these analyses before making a listing
or reimbursement decision on a new healthcare inter-
vention. The impact on a particular budget, that is, the
difference in healthcare expenditures before and after
Tsao et al. Canadian Journal of Kidney Health and Disease 2014, 1:28 Page 3 of 8
http://www.cjkhd.org/content/1/1/28reimbursement or listing of the new intervention, is a com-
monly used measure of forecasting the fiscal impact. A BIA
also can be used for budget planning and resource manage-
ment within an organization. BIA addresses the expected
changes in expenditures from the perspective of a payer, for
a specified period of interest after adoption of the new
intervention. The aim of a BIA is to provide a valid
computing framework (a “model”) that allows users to
apply input values pertinent to their setting to compute the
possible financial and organizational consequences of
coverage decisions for a new healthcare intervention [3].
This paper discusses the estimated economic impact
and costs offsets associated with the uptake and use of
one or more epoetin SEBs in Canada for the treatment
of anemia of CKD. We also hope to inform clinicians,
budget holders, hospital administrators and Pharmacy
and Therapeutics Committee members across Canada as
to the economic impact of the provision of epoetin SEBs
in their respective institutions.
Methods
Model overview
We developed a budget impact model that estimated the
economic consequences and costs offsets associated with
the introduction of epoetin SEBs in Canada. The model was
constructed in Microsoft Excel. The development of this
model followed the Principles of Good Practice for Budget
Impact Analysis II: Report of the International Society of
Pharmacoeconomics and Outcomes Research (ISPOR) Task
Force on Good Research Practices [3], wherever possible.
Model description
The model was designed as a Canada-wide epidemio-
logical-based analysis, and estimated economic outcomes
under two scenarios:
1. ‘Reference scenario’: In the absence of epoetin SEBs
for anemia of CKD treatment in Canada.
2. ‘SEB scenario’: Presence of one or more epoetin
SEBs for anemia of CKD treatment in Canada.
Under the ‘Reference scenario’ arm, the eligible patient
population for treatment with currently available ESAs
and their associated resource utilization and economic
impact were calculated. Under the ‘SEB scenario’ arm,
we assumed that only a subset of the eligible population
would receive treatment with epoetin SEBs, according to
plausible estimates of market uptake.
Time horizon
The budget impact model estimated the economic impact
of adopting epoetin SEBs for anemia treatment over a
five-year time horizon, with cycle lengths of one year. The
model default base year is 2014 and the analysis estimatedthe budget impact in years 2015, 2016, 2017, 2018, and
2019.
Perspective
The budget impact model was built from the perspective of
the Canadian healthcare payer or budget holder. The base
case assumption is that all patients in the model will be
covered under the payer’s budget. Though in Canada, we
do not have a pan-Canadian payer, this perspective can be
adapted to regional payers or budget holders of local
institutions.
Study population
The analysis was performed for patients with CKD
stages III to V, who have renal anemia and require treat-
ment with ESAs. All populations who are candidates for
ESAs were assumed to also be candidates for epoetin
SEBs under the ‘SEB scenario’. The study population
was derived from the projected Canadian population
based on Statistics Canada [4] projections over years
2015 to 2019, and estimated using the disease incidence
and prevalence of CKD stages III/IV not requiring dialy-
sis, and CKD stage V patients requiring dialysis. Based
on the literature, the prevalence of stage III/IV CKD in
Canada is 3.04% and stage V CKD is 0.12%; the inci-
dence of CKD was estimated to be 407.6/100,000 annu-
ally for stages III/IV and 19.2/100,000 annually for stage
V [5-7].
Mortality rates of individuals in CKD stage III/IV are
not well characterised in literature and databases. We
estimated the mortality rate to be approximately 2% an-
nually for this cohort based on a retrospective study
examining the competing risks of progression to end-
stage renal disease and death in non-diabetic CKD [8].
Mortality rates from years 1 to 5 for those with stage V
CKD were obtained from the Canadian Organ Replace-
ment Register and were estimated to be 15% in year 1 to
57% by year 5 [7].
It was estimated that of all CKD stage III/IV patients,
1.86% receive ESAs for the treatment of anemia based on
British Columbia (BC) administrative data; of all individuals
with stage V CKD, approximately 77.5% receive ESAs for
the treatment of anemia. Those in stage III/IV CKD and
those in stage V CKD receiving peritoneal dialysis use sub-
cutaneous ESAs as according to guidelines [9]; and those in
stage V CKD receiving hemodialysis are assumed to receive
intravenous ESAs. The distribution of patients in stage V
CKD on hemodialysis and peritoneal dialysis was also based
on administrative data from BC.
Resource use and costs
Only direct medical costs pertaining to drug acquisition of
currently available ESAs in Canada were incorporated in
the model. No discounting of future costs was applied.
Table 1 Costs of treatment for anemia of chronic kidney disease, by disease stage, prior to SEB introduction
Treatment strategies for anemia of
CKD by disease stage








Stage III/IV short acting ESA (SC) 14.25 4,186 IU 59.65 3,101.83
Stage III/IV long acting ESA (SC) 13.36 21 mcg 62.05 3,226.59
Stage V short acting ESA (SC) 14.25 8,033 IU 114.47 5,952.45
Stage V long acting ESA (SC) 13.36 27 mcg 79.27 4,122.01
Stage V short acting ESA (IV) 14.25 11,475 IU 163.52 8,502.98
Stage V long acting ESA (IV) 13.36 38 mcg 113.71 5,912.84
SEB = subsequent entry biologic; CKD = chronic kidney disease; ESA = erythropoiesis stimulating agents; SC = subcutaneous; IV = intravenous; IU = international units;
mcg =micrograms.
Table 2 Projected uptake rates of epoetin SEB in Canada,
years 1 to 5
Epoetin SEB uptake rates
Year 1 Year 2 Year 3 Year 4 Year 5
1% 4% 7% 11% 14%
SEB = subsequent entry biologic.
Tsao et al. Canadian Journal of Kidney Health and Disease 2014, 1:28 Page 4 of 8
http://www.cjkhd.org/content/1/1/28Currently, the only short acting ESA in Canada is Eprex®
and the only long acting ESA available is Aranesp®. Based
on experiences with biosimilars in the EU, there has been
wide variation in the reduced pricing of biosimilars from
originator products. In general, price reductions of origin-
ator products have also been observed after introduction
of biosimilars. In our model, it was assumed that in the
base case scenario, epoetin SEBs would be 78% of the ori-
ginator price (average in EU) when introduced into the
Canadian market [10]. Furthermore, it was assumed that
upon introduction of an epoetin SEB in the Canadian
market, the originator ESA will drop their price by 13%
(average in EU) in the base case analysis. During a litera-
ture review, we did not find strong evidence suggesting
the development or availability of an Aranesp® SEB; how-
ever, because the market share and cost of Aranesp® would
be impacted by the availability of epoetin SEBs, it was in-
cluded in the analysis.
The drug cost of anemia treatments were obtained from
the Ontario Drug Benefit Formulary [11] and presented as
cost per defined daily dose (DDD) according to the World
Health Organization [12]. Defined daily dose for epoetin is
1,000 IU while the DDD for darbepoetin is 4.5 mcg. Dosing
for anemia treatment is adjusted based on target haemoglo-
bin levels: in the model, median dosages of short acting
ESAs were obtained from published sources [13-16] and
subcutaneous dosages were calculated to be 30% less than
the intravenous dose [9]. We also calculated the dose of
long acting ESA based on a conversion ratio of 200:1 from
short acting ESA doses less than 8000 IU/week and a ratio
of 300:1 for doses greater than 8000 IU/week, due to the
curvilinear relationship of epoetin to darbepoetin dosing
[17]. We also recognized that there would be drug-related
resource utilization costs such as those pertaining to drug
storage, drug administration and healthcare personnel
wages. These costs were considered to be a part of adminis-
trative overhead and were not expected to be significantly
different between comparators. Table 1 shows the annual
cost of treatment for those with anemia of CKD. It is as-
sumed in the base case scenario that epoetin SEBs will re-
quire doses not significantly different from originator drugsin order to achieve the same therapeutic effects, as evi-
denced by clinical trials of epoetin SEBs [18-20].
Market uptake
Forecasted market uptake rates of epoetin SEBs were
based on IMS Health data of overall trends of biosimilar
uptake in the EU and projected for five years after intro-
duction onto the market [21]. Biosimilars of ESAs dom-
inate the overall biosimilar market in EU and in general
the uptake has been slow due to policies preventing
automatic substitution from originator drugs. As ESAs
are used for the chronic treatment of anemia, the pene-
trable market for SEBs consists only of those newly diag-
nosed with anemia, and existing patients continue to be
treated with originator ESAs. The projected uptake rates
of epoetin SEB are presented in Table 2. This is assumed
to be the uptake rate for epoetin SEBs from market
shares of both short acting and long acting originator
ESAs; however, the current market share distribution be-
tween these two drug categories is not known as some
provinces only have one type of ESA and others offer
both. The model employs the assumption that the
current market share distribution is 50% and 50%, be-
tween short and long acting ESAs, respectively. This is a
relatively minor assumption, as it does not have any ef-
fect on the net budget impact.
Sensitivity analysis
One-way sensitivity analysis was performed for model
input variables using plausible ranges of lower and upper
bound estimates, to determine the magnitude of impact
each variable has on the model outcomes. A tornado
diagram was generated to illustrate the impact of each
variable on the budget.
Table 3 Expected number of epoetin SEB users in
Canada, years 1 to 5
Year 1 Year 2 Year 3 Year 4 Year 5
Number of SEB users 982 4,393 8,344 13,785 17,826
SEB = subsequent entry biologic.
Table 5 Total treatment costs for with and without SEB





Year 2 total costs ($)
Without SEB With SEB
Stage III/IV Short acting ESA (SC) 31,736,891 25,402,208
Long acting ESA (SC) 33,013,420 26,423,942
Epoetin SEB - 4,040,419
Stage V Short acting ESA (SC) 26,456,982 21,176,169
Long acting ESA (SC) 18,321,156 14,664,254
Short acting ESA (IV) 108,692,464 86,997,449
Long acting ESA (IV) 75,583,082 60,496,699
Epoetin SEB - 14,292,950
Total 293,803,997 253,494,088
SEB = subsequent entry biologic; CKD = chronic kidney disease;
ESA = erythropoiesis stimulating agents; SC = subcutaneous; IV = intravenous.
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Base case
In the base case scenario, the number of expected patients
with stage III/IV CKD requiring treatment with ESAs for
anemia was 42,644 in the base year (2014). In year 1 the
number of patients increased to 49,104; then to 54,919 in
year 2; 59,600 in year 3; 62,661 in year 4 and 63,665 in
year 5. Given the estimated uptake rate of epoetin SEBs,
we expected to have increasing number of SEB users over
five years, as shown in Table 3.
Assuming that when epoetin SEBs are introduced into
the Canadian market, they will be at 78% of the originator’s
price (as the average in EU), that the originator’s price will
be reduced by 13% and taking into account the cost of
treatment for different stages of CKD, including the num-
ber of patients receiving treatment with ESAs or SEBs, the
expected annual cost of treatment for years 1 to 5 are as
shown in Tables 4, 5, 6, 7 and 8. The ‘Without SEB’ sce-
nario is without the existence of epoetin SEBs and the
‘With SEB’ scenario is with the introduction of epoetin
SEBs over the five-year time horizon.
Table 9 shows the total cost for drugs for the two scenar-
ios for years 1 to 5 and consequently, the incremental
budget impact to the Canadian healthcare system from the
uptake of epoetin SEBs for treatment of anemia in CKD.
Sensitivity analysis
One-way sensitivity analyses were performed using +/−
10% margins for incidence of CKD stages III to V; +/− 20%
margins for proportion of stage III to IV patients treated
with ESAs; and +/− 10% margins for proportion of stage VTable 4 Total treatment costs for with and without SEB





Year 1 total costs ($)
Without SEB With SEB
Stage III/IV Short acting ESA (SC) 28,391,013 24,206,178
Long acting ESA (SC) 29,532,964 25,179,805
Epoetin SEB - 930,614
Stage V Short acting ESA (SC) 23,648,751 20,162,925
Long acting ESA (SC) 16,376,488 13,962,594
Short acting ESA (IV) 97,155,486 82,834,767
Long acting ESA (IV) 67,560,443 57,602,033
Epoetin SEB - 3,193,963
Total 262,665,144 228,045,878
SEB = subsequent entry biologic; CKD = chronic kidney disease;
ESA = erythropoiesis stimulating agents; SC = subcutaneous; IV = intravenous.patients treated with ESAs. Prevalence estimates of CKD
stages III to IV vary widely in literature and upper bounds
of 8.05% were used [22]. Model results were found to be
sensitive to CKD prevalence, as seen in Figure 1. This is
simply due to the fact that CKD prevalence has a direct im-
pact on number of patients treated with ESAs. Therefore,
the higher the prevalence, the more patients receive ESA
treatment, the more cost savings will be brought about if
an SEB were to be taken up in the market. The model out-
come was sensitive to changes in uptake rate of SEBs. For
the uptake rate, we estimated the lower bound to be similar
to UK uptake of epoetin SEBs (3% after 5 years), and the
upper bound to be similar to Germany’s uptake (43% after
5 years), which resulted in a large range of cost savings.
The dose of short acting ESAs was found to trend towards
10% higher with SEBs compared to originators, based on
clinical trials in the EU; in clinical studies this was not
deemed statistically significant and we also found it to have
relatively minor impact on cost savings.Table 6 Total treatment costs for with and without SEB





Year 3 total costs ($)
Without SEB With SEB
Stage III/IV Short acting ESA (SC) 35,043,965 26,219,895
Long acting ESA (SC) 36,453,512 27,274,518
Epoetin SEB - 7,807,525
Stage V Short acting ESA (SC) 28,414,572 21,259,783
Long acting ESA (SC) 19,676,765 14,722,155
Short acting ESA (IV) 116,734,773 87,340,957
Long acting ESA (IV) 81,175,581 60,735,569
Epoetin SEB - 26,863,384
Total 317,499,168 272,223,786
SEB = subsequent entry biologic; CKD = chronic kidney disease;
ESA = erythropoiesis stimulating agents; SC = subcutaneous; IV = intravenous.
Table 7 Total treatment costs for with and without SEB





Year 4 Total costs ($)
Without SEB With SEB
Stage III/IV Short acting ESA (SC) 38,308,544 25,996,178
Long acting ESA (SC) 39,849,400 27,041,803
Epoetin SEB - 13,411,903
Stage V Short acting ESA (SC) 29,148,598 19,780,239
Long acting ESA (SC) 20,185,070 13,697,588
Short acting ESA (IV) 119,750,354 81,262,590
Long acting ESA (IV) 83,272,569 56,508,765
Epoetin SEB - 43,304,392
Total 330,514,535 281,003,457
SEB = subsequent entry biologic; CKD = chronic kidney disease;
ESA = erythropoiesis stimulating agents; SC = subcutaneous; IV = intravenous.
Table 9 Net budget impact due to adoption of epoetin
SEBs for years 1 to 5, and cumulative impact over 5 years
Year Total drug cost
in without SEB
scenario ($)




Year 1 262,665,144 228,045,878 −34,619,266
Year 2 293,803,997 253,494,088 −40,309,908
Year 3 317,499,168 272,223,786 −45,275,381
Year 4 330,514,535 281,003,457 −49,511,077




SEB = subsequent entry biologic.
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This analysis is the first in Canada to estimate the hypo-
thetical economic impact of ESA use for renal anemia
with and without the adoption of epoetin SEBs. It ad-
dresses an important and timely question, as epoetin SEBs
will likely enter the Canadian market in the near future.
Based on our analysis, under market phenomena similar
to those seen in the EU, we could expect that Canadian
adoption of epoetin SEBs would result in $35 million (year
1) to $50 million (year 5) cost savings annually, with cu-
mulative savings of $221 million after 5 years. This
equates to an approximate 14.4% cost difference favoring
SEBs. This does not take into account the potential cost
savings from use of epoetin SEBs for other indications
than management of renal anemia, which was out of the
scope of this analysis.
Other published studies have examined the budget im-
pact of epoetin SEBs for the management of chemother-
apy-induced anemia in European countries, with positive
conclusions [23,24]. Though not directly comparable,Table 8 Total treatment costs for with and without SEB





Year 5 total costs ($)
Without SEB With SEB
Stage III/IV Short acting ESA (SC) 41,530,100 26,014,455
Llong acting ESA (SC) 43,200,535 27,060,815
Epoetin SEB - 18,505,171
Stage V Short acting ESA (SC) 28,324,361 17,742,380
Long acting ESA (SC) 19,614,295 12,286,394
Short acting ESA (IV) 116,364,164 72,890,512
Long acting ESA (IV) 80,917,865 50,686,950
Epoetin SEB - 53,556,198
Total 329,951,320 278,742,875
SEB = subsequent entry biologic; CKD = chronic kidney disease;
ESA = erythropoiesis stimulating agents; SC = subcutaneous; IV = intravenous.Nikolaidi et al. found the budget impact of managing
chemotherapy-induced anemia in newly diagnosed cancer
patients with epoetin SEBs resulted in cost reductions of at
least 10.1%, up to 25.2%, in Greece [23]. Abraham et al.
contended that for this patient population, cost savings
resulting from the use of epoetin SEBs could substantially
increase accessibility to costly neoplastic therapies such as
rituximab, bevacizumab, or trastuzumab [24]. Given that
the most widely accepted indication of ESAs is in renal dis-
ease, and all Canadian provinces publicly fund the use of
ESAs for renal anemia, the potential cost savings to the
healthcare payer from adopting epoetin SEBs can be reallo-
cated towards expanding access to expensive treatments for
patients afflicted with other renal diseases, such as access to
rituximab treatment of glomerulonephritis subtypes.
Health Canada recommends against the interchange
of originator drugs for its SEB in patients already receiv-
ing originator drugs. As such, the estimated uptake rate
of chronic medications as ESAs is modest at best. How-
ever, as seen in the analysis, even conservative uptake of
epoetin SEBs in Canada could result in substantial cost
savings to the healthcare payer. Based on our sensitivity
analysis, the rate of SEB uptake is the key variable that is
amenable to market forces and decision-maker preferences.
We believe that due to the mostly positive experience in the
EU with epoetin SEBs, there is potential for greater accept-
ance of its use when introduced into the Canadian market,
as such the forecasted uptake could be more dramatic. Fur-
thermore, each jurisdiction in Canada is able to make their
own decisions to allow substitution from originator drugs to
SEB, thus if the efficacy and safety of epoetin SEBs are sus-
tained and decision-makers feel confident in its adoption,
greater cost savings could be realized.
A strength of this budget impact analysis is the in-
corporation of reliable sources of data to support the
cost analysis. We utilized administrative data in BC,
which is some of the most comprehensive administra-
tive data in Canada due to availability of a provincial-
wide system that captures all direct costs of healthcare
utilization, including prescription medications for all












Figure 1 Tornado diagram demonstrating cost savings based on one-way sensitivity analyses of varying factors.
Tsao et al. Canadian Journal of Kidney Health and Disease 2014, 1:28 Page 7 of 8
http://www.cjkhd.org/content/1/1/28residents. However, it appears that the proportion of
CKD stage III/IV patients treated for renal anemia with
ESAs was low in this jurisdiction, estimated at 1.86% an-
nually. We took the conservative approach and relied
on BC data; but, other jurisdictions may have higher
estimates. As more clinical data on the efficacy and
safety of epoetin SEBs become available, future budget
impact analyses should take into account outcomes of
treatment with ESAs versus SEBs, such as the cost of
avoided blood transfusions. Being that the uptake rate
of SEBs appears to be a variable of substantial import-
ance, future research should explore the preferences of
stakeholder groups, such as policy makers, hospital ad-
ministrators, physicians, and patients, for adopting, pre-
scribing, or using SEBs.
Conclusion
Biologic medicines are among the most costly pharma-
ceuticals available. It was estimated that biologic drugs
accounted for 14% of the pharmaceuticals market in
Canada, costing the Canadian healthcare system $3 billion
in 2010 [25]. Furthermore, biologics are expected to repre-
sent 20% of the pharmaceutical market over the next
decade which will result in significant financial pressure
on healthcare budgets across the country. The advent of
SEBs represents an opportunity to relieve some of the
financial pressure, if the efficacy and safety of SEBs can be
sustained. Under these assumptions, we have shown that
epoetin SEBs for the management of renal anemia can
lead to substantial cost savings for the Canadian payer if
adopted in the Canadian market. In turn, cost savings can
be applied to expand patient access to under-funded treat-
ments for other renal diseases.Competing interests
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